Pancreatic Cancer Research

ResearcherIRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'OrsolaActive in the last 2 years

Claudio Ricci

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6638-4479; OpenAlex author ID A5011078535. Sources: OpenAlex.

Their work

Papers
31 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
92
Papers, trials and grants by year

2014: 1 paper · 2015: 2 papers · 2016: none · 2017: none · 2018: 2 papers · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: none · 2023: 4 papers · 2024: 8 papers · 2025: 5 papers · 2026: 5 papers

Papers 31

  1. Presumed Intraductal Papillary Mucinous Neoplasms in Individuals at High Risk for Pancreatic Cancer. Co-author DOI 10.1001/jamanetworkopen.2026.35610↗
  2. Predictive factors for long-term survival in pancreatic ductal adenocarcinoma that underwent surgery: a systematic review and meta-analysis of literature. First author DOI 10.1007/s13304-025-02382-z↗
  3. Pancreatic cancer surgery in Italy: an updated snapshot from a national multicentre analysis of outcomes by hospital volume. Co-author DOI 10.1007/s13304-026-02813-5↗
  4. Current practices, barriers and facilitators toward simultaneous care management in patients affected by pancreatic adenocarcinoma: An Italian cross-sectional … Co-author DOI 10.1016/j.dld.2026.05.011↗
  5. The "Big short" of minimally invasive pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. A cost-effectiveness analysis based on randomized trials. Co-author DOI 10.1016/j.hpb.2025.10.014↗
  6. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  7. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  8. Stage IV pancreatic ductal adenocarcinoma (PDAC) with synchronous liver metastasis: are there survival benefits in liver resection? A systematic review and met… First author DOI 10.1016/j.ejso.2025.109598↗
  9. Exploring the Common Mutational Landscape in Cutaneous Melanoma and Pancreatic Cancer. Co-author DOI 10.1111/pcmr.13210↗
  10. Pancreatic cancer resection in the elderly: state of the art, and future challenges. A systematic review. Co-author DOI 10.23736/s2724-5691.25.10527-3↗
  11. Futility of Up-Front Resection for Anatomically Resectable Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2024.2485↗
  12. Clinicopathological predictive factors in long-term survivors who underwent surgery for pancreatic ductal adenocarcinoma: A single-center propensity score matc… Co-author DOI 10.1002/wjs.12397↗
  13. REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives. Co-author DOI 10.1007/s13304-024-01860-0↗
  14. Minimally invasive versus open radical antegrade modular pancreatosplenectomy for pancreatic ductal adenocarcinoma: an entropy balancing analysis. Co-author DOI 10.1016/j.hpb.2023.09.013↗
  15. Cure Probabilities After Resection of Pancreatic Ductal Adenocarcinoma: A Multi-Institutional Analysis of 2554 Patients. Co-author DOI 10.1097/sla.0000000000006166↗
  16. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  17. Outcomes of a 3-Year Prospective Surveillance in Individuals at High Risk of Pancreatic Cancer. Co-author DOI 10.14309/ajg.0000000000002546↗
  18. Dysregulation of a Subset of Circulating and Vesicle-Associated miRNA in Pancreatic Cancer. Co-author DOI 10.3390/ncrna10030029↗
  19. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  20. Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.01.016↗
  21. Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: A retrospective,… Co-author DOI 10.3389/fnut.2023.1065294↗
  22. Corrigendum: Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: a r… Co-author DOI 10.3389/fnut.2023.1212436↗
  23. Improved survival after pancreatic re-resection of positive neck margin in pancreatic cancer patients. A systematic review and network meta-analysis. First author DOI 10.1016/j.ejso.2021.01.001↗
  24. Neoadjuvant Therapy for Resectable Pancreatic Cancer: A New Standard of Care. Pooled Data From 3 Randomized Controlled Trials. Co-author DOI 10.1097/sla.0000000000005126↗
  25. Intraoperative electrochemotherapy in locally advanced pancreatic cancer: indications, techniques and results-a single-center experience. First author DOI 10.1007/s13304-020-00782-x↗
  26. Searching for novel multimodal treatments in oligometastatic pancreatic cancer. Co-author DOI 10.1186/s12885-020-06718-3↗
  27. Organizing pneumonia after pancreatic cancer treatment with nab-paclitaxel and gemcitabine: a case report. Co-author DOI 10.1259/bjrcr.20170086↗
  28. Mutational burden of resectable pancreatic cancer, as determined by whole transcriptome and whole exome sequencing, predicts a poor prognosis. Co-author DOI 10.3892/ijo.2018.4344↗
  29. Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which… Co-author DOI 10.1007/s11605-015-2890-4↗
  30. Characterization of pancreatic ductal adenocarcinoma using whole transcriptome sequencing and copy number analysis by single-nucleotide polymorphism array. Co-author DOI 10.3892/mmr.2015.4344↗
  31. Locally advanced pancreatic cancer: open questions on terminology, diagnosis and management. First author DOI 10.1007/s13304-014-0258-z↗

Closest collaborators

The 25 strongest of 92 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Riccardo Casadei · 21 shared papers, 2014–2026 · strength 3.53
  2. Carlo Ingaldi · 12 shared papers, 2020–2026 · strength 2.55
  3. Vincenzo D’Ambra · 6 shared papers, 2024–2026 · strength 1.75
  4. Roberto Salvia · 6 shared papers, 2023–2026 · strength 0.93
  5. Massimo Falconi · 5 shared papers, 2021–2026 · strength 0.80
  6. Giuseppe Malleo · 5 shared papers, 2023–2024 · strength 0.75
  7. Alessandro Zerbi · 4 shared papers, 2023–2024 · strength 0.59
  8. Silvia Carrara · 3 shared papers, 2024–2026 · strength 0.59
  9. Erica Secchettin · 4 shared papers, 2023–2026 · strength 0.57
  10. Salvatore Paiella · 4 shared papers, 2023–2026 · strength 0.57
  11. Mariacristina Di Marco · 7 shared papers, 2015–2021 · strength 0.55
  12. Ilaria Trestini · 3 shared papers, 2023–2026 · strength 0.54
  13. Giorgio Ercolani · 4 shared papers, 2015–2024 · strength 0.51
  14. Stefano Crippa · 3 shared papers, 2021–2024 · strength 0.50
  15. Fabio Casciani · 3 shared papers, 2024 · strength 0.49
  16. Gabriella Lionetto Lionetto · 3 shared papers, 2024 · strength 0.49
  17. Carla Serra · 6 shared papers, 2015–2021 · strength 0.47
  18. Francesco Minni · 6 shared papers, 2014–2021 · strength 0.43
  19. Claudio Bassi · 3 shared papers, 2023–2024 · strength 0.39
  20. Alessandro Cucchetti · 2 shared papers, 2024 · strength 0.36
  21. Giulio Belfiori · 2 shared papers, 2024 · strength 0.36
  22. Alessandro Ferrero · 2 shared papers, 2024 · strength 0.36
  23. Serena Langella · 2 shared papers, 2024 · strength 0.36
  24. Valentina Arcangeli · 2 shared papers, 2024–2026 · strength 0.31
  25. Marta Puzzono · 2 shared papers, 2024–2026 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.